New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD

The advent of second-generation anti-VEGF drugs is transforming the treatment of exudative age-related macular degeneration (AMD) due to their prolonged efficacy, which allows for fewer injections but at the cost of a higher risk for inflammation. A presentation at the 131st Congress of the French Society of Ophthalmology , held in Paris, France, reviewed the impact of these new approaches.

The therapeutic management of AMD has undergone significant changes in recent years, the most important of which is undoubtedly the introduction of second-generation anti-VEGF agents (brolucizumab, faricimab, and aflibercept 8 mg), with administration schedules that allow up to 5 months between injections.

While these new developments will redefine therapeutic management in AMD, for now, “it remains